oh come on, it's quite obvious. A company that's still calling...

oh come on, it's quite obvious. A company that's still calling PEG-riba standard of care to talk up mediocre results. No momentum at all from yesterday's price rise. Another Australian HCV play (BLT) pulling up sticks on its programme only 2 or 3 weeks ago because there was no interest from partners due to the success (and reducing cost) of the new standard of care. The fact that BIT missed the boat with HCV by so much due in large part to the lack of money to rapidly carry out trials meaning that they need to better fund their HIV programme if they don't want the same thing to happen. Let's see if I'm wrong.